Insulin-like growth factor-1 (IGF-1) as predictor of cardiovascular mortality in heart failure patients: data from the T.O.S.CA. registry.

Adult Heart Failure Humans Insulin-Like Growth Factor I / analysis Kidney Diseases Prognosis Registries Stroke Volume
Chronic heart failure Chronic renal failure Heart failure with reduced ejection fraction IGF-1 deficiency Multiple hormonal deficiency syndrome

Journal

Internal and emergency medicine
ISSN: 1970-9366
Titre abrégé: Intern Emerg Med
Pays: Italy
ID NLM: 101263418

Informations de publication

Date de publication:
09 2022
Historique:
received: 09 01 2022
accepted: 23 03 2022
pubmed: 22 4 2022
medline: 14 9 2022
entrez: 21 4 2022
Statut: ppublish

Résumé

Data from the "Trattamento Ormonale nello Scompenso CArdiaco" (T.O.S.CA) registry showed that heart failure (HF) represents a complex clinical syndrome with different hormonal alterations. Renal failure represents a frequent complication in HF. We evaluated the relationship between renal function and insuline-like growth factor-1 (IGF-1) deficiency and its impact on cardiovascular mortality (CVM) in patients enrolled in the T.O.S.CA. registry. At the enrolment, all subjects underwent chemistry examinations, including circulating hormones and cardiovascular functional tests. COX regression analysis was used to evaluate factors related to CVM during the follow-up period in all populations, in high-risk patients and in the young-adult population. Also, we evaluate the effects of renal function on the CVM. 337 patients (41 deceased) were analyzed. CVM was related to severe renal dysfunction (HR stages IV-V = 4.86), high-risk conditions (HR 2.25), serum IGF-1 (HR 0.42), and HF etiology (HR 5.85 and HR 1.63 for valvular and ischemic etiology, respectively). In high-risk patients, CVM was related to IGF-1 levels, severe renal dysfunction and valvular etiology, whereas in young patients CMV was related to the high-risk pattern and serum IGF-1 levels. Our study showed the clinical and prognostic utility of the IGF-1 assay in patients with HF.

Identifiants

DOI: 10.1007/s11739-022-02980-4 PMID: 35445917 PMC: PMC9463276
pubmed: 35445917
doi: 10.1007/s11739-022-02980-4
pii: 10.1007/s11739-022-02980-4
pmc: PMC9463276
doi:

Substances chimiques

IGF1 protein, human 0
Insulin-Like Growth Factor I 67763-96-6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1651-1660

Investigateurs

A Cittadini (A)
M A ArcopintoSalzano (MA)
L Saccà (L)
M G Monti (MG)
R Napoli (R)
M Matarazzo (M)
F M Stagnaro (FM)
A Schiavo (A)
P Valente (P)
E Bossone (E)
F Ferrara (F)
V Russo (V)
M Malinconico (M)
R Citro (R)
E Guastalamacchia (E)
M Iacoviello (M)
M Leone (M)
V Triggiani (V)
F Cacciatore (F)
C Maiello (C)
C Amarelli (C)
I Mattucci (I)
G Limongelli (G)
D Masarone (D)
P Calabrò (P)
R Calabrò (R)
A D'Andrea (A)
V Maddaloni (V)
G Pacileo (G)
R Scarafile (R)
F Perticone (F)
A Belfiore (A)
A Sci-Acqua (A)
A Cimellaro (A)
P Perrone Filardi (PP)
L Casaretti (L)
S Paolillo (S)
P Gargiulo (P)
A Mancini (A)
A M R Favuzzi (AMR)
C Di Segni (C)
C Bruno (C)
E Vergani (E)
O Vriz (O)
R Castello (R)
A Frigo (A)
M Campo (M)
M R Sorrentino (MR)
P A Modesti (PA)
D Malandrino (D)
R Manfredini (R)
A De Giorgi (A)
F Fabbian (F)
A Puzzo (A)
L Ragusa (L)
L Caliendo (L)
L Carbone (L)
A Frigiola (A)
T Generali (T)
F Giacomazzi (F)
C De Vincentiis (C)
A Ballotta (A)
P Garofalo (P)
G Malizia (G)
T Suzuki (T)
L M Heaney (LM)
D Bruzzese (D)

Informations de copyright

© 2022. The Author(s).

Références

McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599–3726. https://doi.org/10.1093/eurheartj/ehab368
doi: 10.1093/eurheartj/ehab368 pubmed: 34447992
Cook C, Cole G, Asaria P et al (2014) The annual global economic burden of heart failure. Int J Cardiol 171:368–376. https://doi.org/10.1016/j.ijcard.2013.12.028
doi: 10.1016/j.ijcard.2013.12.028 pubmed: 24398230
Arcopinto M, Cittadini A (2014) Hormonal alterations in heart failure: anabolic impairment in chronic heart failure—diagnostic, prognostic and therapeutic issues. Front Horm Res 43:57–69. https://doi.org/10.1159/000360559
doi: 10.1159/000360559 pubmed: 24943298
Cittadini A, Salzano A, Iacoviello M et al (2021) Multiple hormonal and metabolic deficiency syndrome predicts outcome in heart failure: the T.O.S.C.A. Registry. Eur J Prev Cardiol. https://doi.org/10.1093/eurjpc/zwab020
doi: 10.1093/eurjpc/zwab020 pubmed: 33693736
Saccà L (2019) Heart failure as a multiple hormonal deficiency syndrome. Circ Heart Fail 2:151–156. https://doi.org/10.1161/CIRCHEARTFAILURE.108.821892
doi: 10.1161/CIRCHEARTFAILURE.108.821892
Salzano A, Marra AM, Ferrara F et al (2016) Multiple hormone deficiency syndrome in heart failure with preserved ejection fraction. Int J Cardiol 225:1–3. https://doi.org/10.1016/j.ijcard.2016.09.085
doi: 10.1016/j.ijcard.2016.09.085 pubmed: 27689528
Favuzzi AMR, Venuti A, Bruno C et al (2020) Hormonal deficiencies in heart failure with preserved ejection fraction: prevalence and impact on diastolic dysfunction: a pilot study. Eur Rev Med Pharmacol Sci 24:352–361. https://doi.org/10.26355/eurrev_202001_19933
doi: 10.26355/eurrev_202001_19933 pubmed: 31957849
Cittadini A, Saldamarco L, Marra AM et al (2009) Growth hormone deficiency in patients with chronic heart failure and beneficial effects of its correction. J Clin Endocrinol Metab 94:3329–3336. https://doi.org/10.1210/jc.2009-0533
doi: 10.1210/jc.2009-0533 pubmed: 19584187
Anker SD, Volterrani M, Pflaum CD et al (2001) Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J Am Coll Cardiol 38:443–452. https://doi.org/10.1016/s0735-1097(01)01385-7
doi: 10.1016/s0735-1097(01)01385-7 pubmed: 11499736
Napoli R, Guardasole V, Angelini V et al (2003) Acute effects of growth hormone on vascular function in human subjects. J Clin Endocrinol Metab 88:2817–2820. https://doi.org/10.1210/jc.2003-030144
doi: 10.1210/jc.2003-030144 pubmed: 12788893
Arcopinto M, Isgaard J, Marra AM et al (2014) IGF-1 predicts survival in chronic heart failure. Insights from the T.O.S.CA. (Trattamento Ormonale Nello Scompenso CArdiaco) registry. Int J Cardiol 176:1006–1008. https://doi.org/10.1016/j.ijcard.2014.07.003
doi: 10.1016/j.ijcard.2014.07.003 pubmed: 25037691
Arcopinto M, Bobbio E, Bossone E et al (2013) The GH/IGF-1 axis in chronic heart failure. Endocr Metab Immune Disord Drug Targets 13:76–91. https://doi.org/10.2174/1871530311313010010
doi: 10.2174/1871530311313010010 pubmed: 23369140
Petretta M, Colao A, Sardu C et al (2007) NT-proBNP, IGF-I and survival in patients with chronic heart failure. Growth Horm IGF Res 17:288–296. https://doi.org/10.1016/j.ghir.2007.01.020
doi: 10.1016/j.ghir.2007.01.020 pubmed: 17383209
Watanabe S, Tamura T, Ono K et al (2010) Insulin-like growth factor axis (insulin-like growth factor-I/insulin-like growth factor-binding protein-3) as a prognostic predictor of heart failure: association with adiponectin. Eur J Heart Fail 12:1214–1222. https://doi.org/10.1093/eurjhf/hfq166
doi: 10.1093/eurjhf/hfq166 pubmed: 20851819
Chisalita SI, Dahlström U, Arnqvist HJ, Alehagen U (2011) Increased IGF1 levels in relation to heart failure and cardiovascular mortality in an elderly population: impact of ACE inhibitors. Eur J Endocrinol 165:891–898. https://doi.org/10.1530/EJE-11-0584
doi: 10.1530/EJE-11-0584 pubmed: 21976623
Andreassen M, Raymond I, Kistorp C et al (2009) IGF1 as predictor of all cause mortality and cardiovascular disease in an elderly population. Eur J Endocrinol 160:25–31. https://doi.org/10.1530/EJE-08-0452
doi: 10.1530/EJE-08-0452 pubmed: 18931092
Chioncel O, Lainscak M, Seferovic PM et al (2017) Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 19:1574–1585. https://doi.org/10.1002/ejhf.813
doi: 10.1002/ejhf.813 pubmed: 28386917
Teppala S, Shankar A, Sabanayagam C (2010) Association between IGF-1 and chronic kidney disease among US adults. Clin Exp Nephrol 14:440–444. https://doi.org/10.1007/s10157-010-0307-y
doi: 10.1007/s10157-010-0307-y pubmed: 20567872
Jia T, Gama Axelsson T, Heimbürger O et al (2014) IGF-1 and survival in ESRD. Clin J Am Soc Nephrol 9:120–127. https://doi.org/10.2215/CJN.02470213
doi: 10.2215/CJN.02470213 pubmed: 24178975
Ibáñez de Cáceres I, Priego T, Martín AI et al (2002) GH administration and renal IGF-I system in arthritic rats. Life Sci 71:139–151. https://doi.org/10.1016/s0024-3205(02)01640-5
doi: 10.1016/s0024-3205(02)01640-5 pubmed: 12031684
Bossone E, Arcopinto M, Iacoviello M et al (2018) Multiple hormonal and metabolic deficiency syndrome in chronic heart failure: rationale, design, and demographic characteristics of the T.O.S.CA. Registry Intern Emerg Med 13:661–671. https://doi.org/10.1007/s11739-018-1844-8
doi: 10.1007/s11739-018-1844-8 pubmed: 29619769
Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612. https://doi.org/10.7326/0003-4819-150-9-200905050-00006
doi: 10.7326/0003-4819-150-9-200905050-00006 pubmed: 19414839 pmcid: 2763564
Levey AS, Eckardt KU, Tsukamoto Y et al (2005) Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 67:2089–2100. https://doi.org/10.1111/j.1523-1755.2005.00365.x
doi: 10.1111/j.1523-1755.2005.00365.x pubmed: 15882252
Faxén UL, Hage C, Benson L et al (2017) HFpEF and HFrEF display different phenotypes as assessed by IGF-1 and IGFBP-1. J Card Fail 23:293–303. https://doi.org/10.1016/j.cardfail.2016.06.008
doi: 10.1016/j.cardfail.2016.06.008 pubmed: 27327968
Kang J, Park JJ, Cho YJ et al (2018) Predictors and prognostic value of worsening renal function during admission in HFpEF Versus HFrEF: data from the KorAHF (Korean Acute Heart Failure) Registry. J Am Heart Assoc 7:e007910. https://doi.org/10.1161/JAHA.117.007910
doi: 10.1161/JAHA.117.007910 pubmed: 29535141 pmcid: 5907555
Oremus M, Don-Wauchope A, McKelvie R et al (2014) BNP and NT-proBNP as prognostic markers in persons with chronic stable heart failure. Heart Fail Rev 19:471–505. https://doi.org/10.1007/s10741-014-9439-6
doi: 10.1007/s10741-014-9439-6 pubmed: 24986335
Fabbian F, De Giorgi A, Pala M et al (2013) Predictive value of admission N-terminal pro-B-type natriuretic peptide and renal function in older people hospitalized for dyspnoea. Dis Markers 35:735–740. https://doi.org/10.1155/2013/687467
doi: 10.1155/2013/687467 pubmed: 24324290 pmcid: 3845254
Cittadini A, Marra AM, Arcopinto M et al (2013) Growth hormone replacement delays the progression of chronic heart failure combined with growth hormone deficiency: an extension of a randomized controlled single-blind study. JACC Heart Fail 1:325–330. https://doi.org/10.1016/j.jchf.2013.04.003
doi: 10.1016/j.jchf.2013.04.003 pubmed: 24621936
Bilbao A, Escobar A, García-Perez L et al (2016) The Minnesota living with heart failure questionnaire: comparison of different factor structures. Health Qual Life Outcomes 14:23. https://doi.org/10.1186/s12955-016-0425-7
doi: 10.1186/s12955-016-0425-7 pubmed: 26887590 pmcid: 4756518
Amirpour A, Vakhshoori M, Zavar R et al (2021) The effect of 3-month growth hormone administration and 12-month follow-up duration among heart failure patients four weeks after myocardial infarction: a randomized double-blinded clinical trial. Cardiovasc Ther 2021:2680107. https://doi.org/10.1155/2021/2680107
doi: 10.1155/2021/2680107 pubmed: 33552234 pmcid: 7847345
Le Corvoisier P, Hittinger L, Chanson P et al (2007) Cardiac effects of growth hormone treatment in chronic heart failure: a meta-analysis. J Clin Endocrinol Metab 92:180–185. https://doi.org/10.1210/jc.2006-1313
doi: 10.1210/jc.2006-1313 pubmed: 17062772
Ravassa S, Beaumont J, Cediel G et al (2020) Cardiorenal interaction and heart failure outcomes. a role for insulin-like growth factor binding protein 2? Rev Esp Cardiol (Engl Ed) 73:835–843. https://doi.org/10.1016/j.rec.2019.10.012
doi: 10.1016/j.rec.2019.10.012
Ferry RJ Jr, Cerri RW, Cohen P (1999) Insulin-like growth factor binding proteins: new proteins, new functions. Horm Res 51:53–67. https://doi.org/10.1159/000023315
doi: 10.1159/000023315 pubmed: 10352394
Barutaut M, Fournier P, Peacock WF et al (2020) Insulin-like growth factor binding protein 2 predicts mortality risk in heart failure. Int J Cardiol 300:245–251. https://doi.org/10.1016/j.ijcard.2019.09.032
doi: 10.1016/j.ijcard.2019.09.032 pubmed: 31806281
Li Y, Li L, Wang C (2021) Insulin-like growth factor binding protein 2 might be a novel therapeutic target in the treatment of heart failure. Int J Cardiol 332:163. https://doi.org/10.1016/j.ijcard.2021.03.045
doi: 10.1016/j.ijcard.2021.03.045 pubmed: 33753188
Kang H, Zhang J, Zhang X et al (2020) Effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease: a meta-analysis. Eur J Pharmacol 884:173444. https://doi.org/10.1016/j.ejphar.2020.173444
doi: 10.1016/j.ejphar.2020.173444 pubmed: 32739172
Spannella F, Marini M, Giulietti F et al (2019) Renal effects of Sacubitril/Valsartan in heart failure with reduced ejection fraction: a real life 1-year follow-up study. Intern Emerg Med 14:1287–1297. https://doi.org/10.1007/s11739-019-02111-6
doi: 10.1007/s11739-019-02111-6 pubmed: 31147823 pmcid: 6853858
Januzzi JL Jr, Packer M, Claggett B et al (2018) IGFBP7 (insulin-like growth factor-binding protein-7) and neprilysin inhibition in patients with heart failure. Circ Heart Fail 11:e005133. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005133
doi: 10.1161/CIRCHEARTFAILURE.118.005133 pubmed: 30354399
Surya S, Symons K, Rothman E, Barkan AL (2006) Complex rhythmicity of growth hormone secretion in humans. Pituitary 9:121–125. https://doi.org/10.1007/s11102-006-9079-5
doi: 10.1007/s11102-006-9079-5 pubmed: 16845601
Ribeiro-Oliveira A Jr, Abrantes MM, Barkan AL (2013) Complex rhythmicity and age dependence of growth hormone secretion are preserved in patients with acromegaly: further evidence for a present hypothalamic control of pituitary somatotropinomas. J Clin Endocrinol Metab 98:2959–2966. https://doi.org/10.1210/jc.2013-1581
doi: 10.1210/jc.2013-1581 pubmed: 23640965 pmcid: 3701276
Giovannini S, Cesari M, Marzetti E et al (2010) Effects of ACE-inhibition on IGF-1 and IGFBP-3 concentrations in older adults with high cardiovascular risk profile. J Nutr Health Aging 14:457–460. https://doi.org/10.1007/s12603-010-0036-7
doi: 10.1007/s12603-010-0036-7 pubmed: 20617288 pmcid: 4311891
Maggio M, Lauretani F, De Vita F et al (2014) Relationship between use of proton pump inhibitors and IGF system in older subjects. J Nutr Health Aging 18:420–423. https://doi.org/10.1007/s12603-013-0430-z
doi: 10.1007/s12603-013-0430-z pubmed: 24676324 pmcid: 5077149
Mangieri E, Tosti-Croce C, Tanzilli G et al (1996) Changes in growth hormone/insulin-like growth factor-1 axis in patients with normal pituitary function and biventricular cardiac failure and hepatic stasis. Cardiologia 41:449–453
pubmed: 8767634
Assy N, Pruzansky Y, Gaitini D et al (2008) Growth hormone-stimulated IGF-1 generation in cirrhosis reflects hepatocellular dysfunction. J Hepatol 49:34–42. https://doi.org/10.1016/j.jhep.2008.02.013
doi: 10.1016/j.jhep.2008.02.013 pubmed: 18456366

Auteurs

Alfredo De Giorgi (A)

Clinica Medica Unit, Azienda Ospedaliero-Universitaria S.Anna, Ferrara, Italy. alfredo.degiorgi@unife.it.
ORCID: 0000-0002-0903-7825

Alberto Maria Marra (AM)

Department of Translational Medical Sciences, Federico II University, Naples, Italy. alberto_marra@hotmail.it.
Italian Clinical Outcome Research and Reporting Program (I-CORRP)-Center for Pulmonary Hypertension, Thorax Clinic at Heidelberg University Hospital, Heidelberg, Germany. alberto_marra@hotmail.it.

Massimo Iacoviello (M)

Cardiology Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.

Vincenzo Triggiani (V)

Interdisciplinary Department of Medicine-Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases, University of Bari 'A Moro', Bari, Italy.

Giuseppe Rengo (G)

Department of Translational Medical Sciences, Federico II University, Naples, Italy.
Istituti Clinici Scientifici Maugeri SpA Società Benefit-IRCCS-Scientific Institute of Telese Terme, Telese Terme, Italy.

Francesco Cacciatore (F)

Department of Translational Medical Sciences, Federico II University, Naples, Italy.

Ciro Maiello (C)

Heart Transplantation Unit, Monaldi Hospital, Azienda Ospedaliera dei Colli, Naples, Italy.

Giuseppe Limongelli (G)

Division of Cardiology, Monaldi Hospital, Azienda Ospedaliera dei Colli, University of Campania L. Vanvitelli, Caserta, Italy.

Daniele Masarone (D)

Division of Cardiology, Monaldi Hospital, Azienda Ospedaliera dei Colli, University of Campania L. Vanvitelli, Caserta, Italy.

Francesco Perticone (F)

Department of Medical and Surgical Sciences, University Magna Græcia of Catanzaro, Catanzaro, Italy.

Pasquale Perrone Filardi (PP)

Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy.
Mediterranea Cardiocentro, Naples, Italy.

Stefania Paolillo (S)

Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy.
Mediterranea Cardiocentro, Naples, Italy.

Antonio Mancini (A)

Operative Unit of Endocrinology, Catholic University of the Sacred Heart, Rome, Italy.

Maurizio Volterrani (M)

Department of Medical Sciences, IRCCS San Raffaele Pisana, Rome, Italy.

Olga Vriz (O)

Heart Center Department, King Faisal Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia.

Roberto Castello (R)

Division of General Medicine, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Andrea Passantino (A)

Scientific Clinical Institutes Maugeri, IRCCS, Pavia, Italy.

Michela Campo (M)

Unit of Endocrinology and Metabolic Diseases, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.

Pietro Amedeo Modesti (PA)

Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, Florence, Italy.

Andrea Salzano (A)

Italian Clinical Outcome Research and Reporting Program (I-CORRP)-IRCCS SDN, Diagnostic and Nuclear Research Institute, Naples, Italy.

Roberta D'Assante (R)

Department of Translational Medical Sciences, Federico II University, Naples, Italy.
Italian Clinical Outcome Research and Reporting Program (I-CORRP), Naples, Italy.

Michele Arcopinto (M)

Department of Translational Medical Sciences, Federico II University, Naples, Italy.
Italian Clinical Outcome Research and Reporting Program (I-CORRP), Naples, Italy.

Valeria Raparelli (V)

Department of Translational Medicine, University of Ferrara, Ferrara, Italy.

Fabio Fabbian (F)

Clinica Medica Unit, Azienda Ospedaliero-Universitaria S.Anna, Ferrara, Italy.
Department of Medical Sciences, University of Ferrara, Ferrara, Italy.

Angela Sciacqua (A)

Department of Medical and Surgical Sciences, University Magna Græcia of Catanzaro, Catanzaro, Italy.

Annamaria Colao (A)

Clinical Medicine and Surgery Department, Federico II University, Naples, Italy.

Toru Suzuki (T)

Department of Cardiovascular Sciences and NIHR Leicester Biomedical Research Centre, University of Leicester, Glenfield Hospital, Leicester, UK.

Eduardo Bossone (E)

Italian Clinical Outcome Research and Reporting Program (I-CORRP)-Cardiology Division, A. Cardarelli Hospital, Naples, Italy.

Antonio Cittadini (A)

Department of Translational Medical Sciences, Federico II University, Naples, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Insulin-like growth factor-1 (IGF-1) as...
questionsmedicales.fr › Maladies cardiovasculaires › Cardiopathies › Défaillance cardiaque › Insulin-like growth factor-1 (IGF-1) as...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Insulin-like growth factor-1 (IGF-1) as...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Somatomédines › Facteur de croissance IGF-I › Insulin-like growth factor-1 (IGF-1) as...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Maladies du rein › Insulin-like growth factor-1 (IGF-1) as...
questionsmedicales.fr › Diagnostic › Pronostic › Insulin-like growth factor-1 (IGF-1) as...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Enregistrements › Insulin-like growth factor-1 (IGF-1) as...
questionsmedicales.fr › Phénomènes physiologiques respiratoires et circulatoires › Phénomènes physiologiques cardiovasculaires › Hémodynamique › Débit cardiaque › Débit systolique › Insulin-like growth factor-1 (IGF-1) as...